Use the hyperlinks, where available to access additional clinical trial information.
A Phase I/II, Open-Label, Multicentre Study to Investigate the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AZD4205 as Monotherapy or in Combination With Osimertinib in Patients With EGFR Mutant Advanced Stage Non-Small Cell Lung Cancer (NSCLC)
Dizal (Jiangsu) Pharmaceutical Co., Ltd.
This study will treat patients with advanced NSCLC who have progressed following prior therapy. This is the first time this drug has ever been tested in patients, and so it will help to understand what type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body and preliminarily assess its anti-cancer activity as monotherapy and in combination with Osimertinib. This study includes dose escalation part and dose expansion part. In this study, participants will receive a daily dose of AZD4205, followed by daily dose of AZD4205 and Osimertinib 80 mg. The starting dose of AZD4205 will be 75 mg, administered once daily. If tolerated, subsequent cohorts will test increasing doses of AZD4205, and in combination with Osimertinib 80 mg.